CORONA: Revenue grew 22.2% as Q2 EBITDA margin held at 21.7%

What happened

Corona Remedies reported Q2FY27 revenue growth of 22.2% year over year, while its EBITDA margin, meaning earnings before interest, taxes, depreciation and amortization as a share of revenue, stayed at 21.7%. First-half revenue grew 22.0%, and the EBITDA margin increased to 21.9%. Domestic growth outpaced the IPM.

Confirmed

Global impact / market context

Revenue growth alongside a steady quarterly EBITDA margin suggests the company increased sales without reducing this measure of operating profitability. That may support cash generation, but the summary gives no cash-flow figures. Higher depreciation and amortization weighed on PAT margin, meaning net profit as a share of revenue, limiting the benefit reaching shareholders.

Analyst inference

The reported figures show faster domestic growth than the IPM, the market measure referenced in the summary, but do not quantify the gap or explain its cause. Without details on product mix, costs, or cash flow, investors cannot tell whether growth is translating into stronger underlying returns.

Analyst inference

What to watch

1. Future quarterly results can show whether revenue keeps growing while the EBITDA margin stays near 21.7%, or whether costs begin to reduce operating profitability. Analyst inference
2. Watch for updates on depreciation and amortization, which spread asset costs over time, to see whether their effect on PAT margin continues or eases. Analyst inference
3. Further reporting on domestic growth versus the IPM could clarify whether the company is sustaining its relative pace; the supplied summary gives no detailed comparison. Analyst inference

Evidence

• Original source link unavailable